{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:06:12Z","timestamp":1782515172637,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,10,12]],"date-time":"2012-10-12T00:00:00Z","timestamp":1350000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2012,10,12]],"date-time":"2012-10-12T00:00:00Z","timestamp":1350000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness. Prior trials have demonstrated the efficacy of pregabalin for the relief of fibromyalgia symptoms, and it is approved for the treatment of fibromyalgia in the United States. However, prior to this study, there has not been a large-scale efficacy trial in patients with fibromyalgia in Japan.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>This randomized, double-blind, multicenter, placebo-controlled trial was conducted at 44 centers in Japan to assess the efficacy and safety of pregabalin for the symptomatic relief of pain in fibromyalgia patients. Patients aged \u226518 years who had met the criteria for fibromyalgia were randomized to receive either pregabalin, starting at 150 mg\/day and increasing to a maintenance dose of 300 or 450 mg\/day, or placebo, for 15 weeks. The primary efficacy endpoint was mean pain score at final assessment. Secondary endpoints included Patient Global Impression of Change (PGIC) together with measures of sleep, physical functioning and quality of life.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>A total of 498 patients (89% female) were randomized to receive either pregabalin (<jats:italic>n<\/jats:italic> = 250) or placebo (<jats:italic>n<\/jats:italic> = 248). Pregabalin significantly reduced mean pain score at final assessment (difference in mean change from baseline, compared with placebo -0.44; <jats:italic>P<\/jats:italic> = 0.0046) and at every week during the study (<jats:italic>P<\/jats:italic> &lt;0.025). Key secondary endpoints were also significantly improved with pregabalin treatment compared with placebo, including PGIC (percentage reporting symptoms \"very much improved\" or \"much improved\", 38.6% vs 26.7% with placebo; <jats:italic>P<\/jats:italic> = 0.0078); pain visual analog scale (difference in mean change from baseline, compared with placebo -6.19; <jats:italic>P<\/jats:italic> = 0.0013); Fibromyalgia Impact Questionnaire total score (-3.33; <jats:italic>P<\/jats:italic> = 0.0144); and quality of sleep score (-0.73; <jats:italic>P<\/jats:italic> &lt;0.0001). Treatment was generally well tolerated, with somnolence and dizziness the most frequently reported adverse events.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>This trial demonstrated that pregabalin, at doses of up to 450 mg\/day, was effective for the symptomatic relief of pain in Japanese patients with fibromyalgia. Pregabalin also improved measures of sleep and functioning and was well tolerated. These data indicate that pregabalin is an effective treatment option for the relief of pain and sleep problems in Japanese patients with fibromyalgia.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial Registration<\/jats:title>\n                        <jats:p>ClinicalTrials.gov: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00830167\">NCT00830167<\/jats:ext-link><\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4056","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T21:22:09Z","timestamp":1355779329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia"],"prefix":"10.1186","volume":"14","author":[{"given":"Hiroyoshi","family":"Ohta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ohkura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusuki","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,12]]},"reference":[{"key":"3798_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/art.1780330203","volume":"33","author":"F Wolfe","year":"1990","unstructured":"Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990, 33: 160-172. 10.1002\/art.1780330203.","journal-title":"Arthritis Rheum"},{"key":"3798_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1521-6942(03)00035-4","volume":"17","author":"DJ Clauw","year":"2003","unstructured":"Clauw DJ, Crofford LJ: Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003, 17: 685-701. 10.1016\/S1521-6942(03)00035-4.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3798_CR3","first-page":"6","volume":"75","author":"P Mease","year":"2005","unstructured":"Mease P: Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005, 75: 6-21.","journal-title":"J Rheumatol Suppl"},{"key":"3798_CR4","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.3899\/jrheum.090367","volume":"36","author":"P Mease","year":"2009","unstructured":"Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA: Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009, 36: 2318-2329. 10.3899\/jrheum.090367.","journal-title":"J Rheumatol"},{"key":"3798_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010, 62: 600-610. 10.1002\/acr.20140.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3798_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.23826","volume":"59","author":"PJ Mease","year":"2008","unstructured":"Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, Abetz L, Martin SA: Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008, 59: 952-960. 10.1002\/art.23826.","journal-title":"Arthritis Rheum"},{"key":"3798_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/art.1780380104","volume":"38","author":"F Wolfe","year":"1995","unstructured":"Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995, 38: 19-28. 10.1002\/art.1780380104.","journal-title":"Arthritis Rheum"},{"key":"3798_CR8","first-page":"35","volume":"24","author":"M Matsumoto","year":"2006","unstructured":"Matsumoto M: Epidemiology of fibromyalgia. Pharma Medica. 2006, 24: 35-39. Japanese","journal-title":"Pharma Medica"},{"issue":"Suppl 1","key":"3798_CR9","doi-asserted-by":"publisher","first-page":"O5","DOI":"10.1186\/ar3560","volume":"14","author":"K Nishioka","year":"2012","unstructured":"Nishioka K: Research platform for fibromyalgia in Japan. Arthritis Res Ther. 2012, 14 (Suppl 1): O5-10.1186\/ar3560.","journal-title":"Arthritis Res Ther"},{"key":"3798_CR10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","volume":"9","author":"LM Arnold","year":"2008","unstructured":"Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP, Sharma U, Martin SA, Barrett JA, Haig G: A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008, 9: 792-805. 10.1016\/j.jpain.2008.03.013.","journal-title":"J Pain"},{"key":"3798_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pain.2008.02.027","volume":"136","author":"LJ Crofford","year":"2008","unstructured":"Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin SA, Haig GM, Sharma U: Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008, 136: 419-431. 10.1016\/j.pain.2008.02.027.","journal-title":"Pain"},{"key":"3798_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/art.20983","volume":"52","author":"LJ Crofford","year":"2005","unstructured":"Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP, LaMoreaux LK, Martin SA, Sharma U: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005, 52: 1264-1273. 10.1002\/art.20983.","journal-title":"Arthritis Rheum"},{"key":"3798_CR13","first-page":"502","volume":"35","author":"PJ Mease","year":"2008","unstructured":"Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U: A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008, 35: 502-514.","journal-title":"J Rheumatol"},{"key":"3798_CR14","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3899\/jrheum.110569","volume":"38","author":"L Pauer","year":"2011","unstructured":"Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, Leon T, Zeiher B: An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol. 2011, 38: 2643-2652. 10.3899\/jrheum.110569.","journal-title":"J Rheumatol"},{"key":"3798_CR15","doi-asserted-by":"publisher","first-page":"17537","DOI":"10.1073\/pnas.0409066103","volume":"103","author":"MJ Field","year":"2006","unstructured":"Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D: Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006, 103: 17537-17542. 10.1073\/pnas.0409066103.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3798_CR16","unstructured":"Pfizer Inc: LYRICA prescribing information. [http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=561]"},{"key":"3798_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, et al: Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008, 9: 105-121. 10.1016\/j.jpain.2007.09.005.","journal-title":"J Pain"},{"key":"3798_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001, 94: 149-158. 10.1016\/S0304-3959(01)00349-9.","journal-title":"Pain"},{"key":"3798_CR19","first-page":"728","volume":"18","author":"CS Burckhardt","year":"1991","unstructured":"Burckhardt CS, Clark SR, Bennett RM: The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991, 18: 728-733.","journal-title":"J Rheumatol"},{"key":"3798_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1756-185X.2010.01585.x","volume":"14","author":"K Osada","year":"2011","unstructured":"Osada K, Oka H, Isomura T, Nakamura I, Tominaga K, Takahashi S, Kojima A, Nishioka K: Development of the Japanese version of the Fibromyalgia Impact Questionnaire (JFIQ): psychometric assessments of reliability and validity. Int J Rheum Dis. 2011, 14: 74-80. 10.1111\/j.1756-185X.2010.01585.x.","journal-title":"Int J Rheum Dis"},{"key":"3798_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097\/00005650-199206000-00002.","journal-title":"Med Care"},{"key":"3798_CR22","volume-title":"The Hospital Anxiety and Depression Scale Manual","author":"RP Snaith","year":"1994","unstructured":"Snaith RP, Zigmond AS: The Hospital Anxiety and Depression Scale Manual. 1994, London: NFER Nelson"},{"key":"3798_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-7-54","volume":"7","author":"JC Cappelleri","year":"2009","unstructured":"Cappelleri JC, Bushmakin AG, McDermott AM, Sadosky AB, Petrie CD, Martin S: Psychometric properties of a single-item scale to assess sleep quality among individuals with fibromyalgia. Health Qual Life Outcomes. 2009, 7: 54-10.1186\/1477-7525-7-54.","journal-title":"Health Qual Life Outcomes"},{"key":"3798_CR24","first-page":"235","volume-title":"Measuring Functioning and Well-Being","author":"RD Hays","year":"1992","unstructured":"Hays RD, Stewart AL: Sleep measures. Measuring Functioning and Well-Being. Edited by: Stewart AL, Ware JE Jr. 1992, Durham, NC: Duke University Press, 235-239."},{"key":"3798_CR25","first-page":"S154","volume":"23","author":"R Bennett","year":"2005","unstructured":"Bennett R: The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005, 23: S154-162.","journal-title":"Clin Exp Rheumatol"},{"key":"3798_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/00000441-199806000-00005","volume":"315","author":"SM Harding","year":"1998","unstructured":"Harding SM: Sleep in fibromyalgia patients: subjective and objective findings. Am J Med Sci. 1998, 315: 367-376. 10.1097\/00000441-199806000-00005.","journal-title":"Am J Med Sci"},{"key":"3798_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.rdc.2009.05.008","volume":"35","author":"H Moldofsky","year":"2009","unstructured":"Moldofsky H: The significance of dysfunctions of the sleeping\/waking brain to the pathogenesis and treatment of fibromyalgia syndrome. Rheum Dis Clin North Am. 2009, 35: 275-283. 10.1016\/j.rdc.2009.05.008.","journal-title":"Rheum Dis Clin North Am"},{"key":"3798_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/art.23828","volume":"59","author":"SM Bigatti","year":"2008","unstructured":"Bigatti SM, Hernandez AM, Cronan TA, Rand KL: Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum. 2008, 59: 961-967. 10.1002\/art.23828.","journal-title":"Arthritis Rheum"},{"key":"3798_CR29","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1212\/WNL.0b013e3181e1ce73","volume":"74","author":"D Garcia-Borreguero","year":"2010","unstructured":"Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, Fernandez C: Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010, 74: 1897-1904. 10.1212\/WNL.0b013e3181e1ce73.","journal-title":"Neurology"},{"key":"3798_CR30","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","volume":"60","author":"RH Dworkin","year":"2003","unstructured":"Dworkin RH, Corbin AE, Young JP, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM: Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003, 60: 1274-1283. 10.1212\/01.WNL.0000055433.55136.55.","journal-title":"Neurology"},{"key":"3798_CR31","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1212\/01.wnl.0000244422.45278.ff","volume":"67","author":"PJ Siddall","year":"2006","unstructured":"Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK: Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology. 2006, 67: 1792-1800. 10.1212\/01.wnl.0000244422.45278.ff.","journal-title":"Neurology"},{"key":"3798_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","volume":"115","author":"R Freynhagen","year":"2005","unstructured":"Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M: Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005, 115: 254-263. 10.1016\/j.pain.2005.02.032.","journal-title":"Pain"},{"key":"3798_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1185\/030079906X80404","volume":"22","author":"R van Seventer","year":"2006","unstructured":"van Seventer R, Feister HA, Young JP, Stoker M, Versavel M, Rigaudy L: Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006, 22: 375-384. 10.1185\/030079906X80404.","journal-title":"Curr Med Res Opin"},{"key":"3798_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/acr.21595","volume":"64","author":"T Roth","year":"2012","unstructured":"Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM: Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken). 2012, 64: 597-606.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3798_CR35","first-page":"CD007076","volume-title":"Cochrane Database Syst Rev","author":"RA Moore","year":"2009","unstructured":"Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ: Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009, CD007076-"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4056\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:46:12Z","timestamp":1728384372000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,12]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,10]]}},"alternative-id":["3798"],"URL":"https:\/\/doi.org\/10.1186\/ar4056","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,12]]},"assertion":[{"value":"17 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R217"}}